CD274 and non-small cell lung carcinoma: For instance, blocking PD1-PD-L1 immune checkpoints with antibodies (e.g. nivolumab and pembrolizumab) result in improved therapy response in non-small cell lung cancer (NSCLC), melanoma, and their corresponding brain metastases [3, 4].